vs

Side-by-side financial comparison of ASCENT INDUSTRIES CO. (ACNT) and Lineage Cell Therapeutics, Inc. (LCTX). Click either name above to swap in a different company.

ASCENT INDUSTRIES CO. is the larger business by last-quarter revenue ($11.9M vs $6.6M, roughly 1.8× Lineage Cell Therapeutics, Inc.). Lineage Cell Therapeutics, Inc. runs the higher net margin — 12.9% vs -8.8%, a 21.6% gap on every dollar of revenue. On growth, Lineage Cell Therapeutics, Inc. posted the faster year-over-year revenue change (130.4% vs 13.3%). ASCENT INDUSTRIES CO. produced more free cash flow last quarter ($-196.0K vs $-5.3M). Over the past eight quarters, Lineage Cell Therapeutics, Inc.'s revenue compounded faster (113.9% CAGR vs -34.9%).

Ascent Capital Group, Inc. was a publicly traded holding company whose primary subsidiary was Monitronics. Ascent Media was a wholly owned subsidiary of the Discovery Holding Company (DHC). DHC spun off Ascent Media as an independent, public company on September 17, 2008.

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

ACNT vs LCTX — Head-to-Head

Bigger by revenue
ACNT
ACNT
1.8× larger
ACNT
$11.9M
$6.6M
LCTX
Growing faster (revenue YoY)
LCTX
LCTX
+117.1% gap
LCTX
130.4%
13.3%
ACNT
Higher net margin
LCTX
LCTX
21.6% more per $
LCTX
12.9%
-8.8%
ACNT
More free cash flow
ACNT
ACNT
$5.1M more FCF
ACNT
$-196.0K
$-5.3M
LCTX
Faster 2-yr revenue CAGR
LCTX
LCTX
Annualised
LCTX
113.9%
-34.9%
ACNT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACNT
ACNT
LCTX
LCTX
Revenue
$11.9M
$6.6M
Net Profit
$-1.0M
$851.0K
Gross Margin
14.6%
Operating Margin
-21.0%
-99.1%
Net Margin
-8.8%
12.9%
Revenue YoY
13.3%
130.4%
Net Profit YoY
-1.2%
126.0%
EPS (diluted)
$-0.11
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACNT
ACNT
LCTX
LCTX
Q4 25
$11.9M
$6.6M
Q3 25
$19.7M
$3.7M
Q2 25
$18.7M
$2.8M
Q1 25
$24.7M
$1.5M
Q4 24
$10.5M
$2.9M
Q3 24
$20.9M
$3.8M
Q2 24
$21.5M
$1.4M
Q1 24
$28.0M
$1.4M
Net Profit
ACNT
ACNT
LCTX
LCTX
Q4 25
$-1.0M
$851.0K
Q3 25
$-2.1M
$-29.8M
Q2 25
$6.3M
$-30.5M
Q1 25
$-2.3M
$-4.1M
Q4 24
$-1.0M
$-3.3M
Q3 24
$-6.2M
$-3.0M
Q2 24
$-926.0K
$-5.8M
Q1 24
$-5.5M
$-6.5M
Gross Margin
ACNT
ACNT
LCTX
LCTX
Q4 25
14.6%
Q3 25
29.7%
Q2 25
26.1%
Q1 25
19.3%
97.6%
Q4 24
24.3%
94.6%
Q3 24
14.4%
99.0%
Q2 24
13.1%
96.9%
Q1 24
8.3%
93.2%
Operating Margin
ACNT
ACNT
LCTX
LCTX
Q4 25
-21.0%
-99.1%
Q3 25
-4.1%
-102.9%
Q2 25
-14.4%
-715.4%
Q1 25
-4.2%
-433.1%
Q4 24
-25.4%
-178.2%
Q3 24
-9.4%
-101.6%
Q2 24
-8.6%
-416.7%
Q1 24
-15.5%
-461.3%
Net Margin
ACNT
ACNT
LCTX
LCTX
Q4 25
-8.8%
12.9%
Q3 25
-10.6%
-809.0%
Q2 25
33.7%
-1101.8%
Q1 25
-9.3%
-275.6%
Q4 24
-9.8%
-114.1%
Q3 24
-29.5%
-80.3%
Q2 24
-4.3%
-409.1%
Q1 24
-19.7%
-453.0%
EPS (diluted)
ACNT
ACNT
LCTX
LCTX
Q4 25
$-0.11
$0.00
Q3 25
$-0.22
$-0.13
Q2 25
$0.65
$-0.13
Q1 25
$-0.23
$-0.02
Q4 24
$-0.11
$0.00
Q3 24
$-0.61
$-0.02
Q2 24
$-0.09
$-0.03
Q1 24
$-0.54
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACNT
ACNT
LCTX
LCTX
Cash + ST InvestmentsLiquidity on hand
$57.6M
$55.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$87.0M
$44.5M
Total Assets
$111.9M
$112.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACNT
ACNT
LCTX
LCTX
Q4 25
$57.6M
$55.8M
Q3 25
$58.0M
$40.5M
Q2 25
$60.5M
$42.3M
Q1 25
$14.3M
$47.9M
Q4 24
$16.1M
$47.8M
Q3 24
$8.5M
$32.7M
Q2 24
$3.6M
$38.5M
Q1 24
$1.3M
$43.6M
Total Debt
ACNT
ACNT
LCTX
LCTX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ACNT
ACNT
LCTX
LCTX
Q4 25
$87.0M
$44.5M
Q3 25
$87.1M
$22.0M
Q2 25
$89.7M
$48.4M
Q1 25
$91.2M
$79.0M
Q4 24
$93.5M
$78.4M
Q3 24
$94.7M
$66.2M
Q2 24
$101.0M
$68.3M
Q1 24
$102.0M
$72.4M
Total Assets
ACNT
ACNT
LCTX
LCTX
Q4 25
$111.9M
$112.6M
Q3 25
$119.9M
$89.6M
Q2 25
$122.6M
$90.8M
Q1 25
$152.5M
$111.8M
Q4 24
$147.3M
$113.2M
Q3 24
$148.6M
$96.6M
Q2 24
$158.2M
$102.8M
Q1 24
$161.0M
$108.5M
Debt / Equity
ACNT
ACNT
LCTX
LCTX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACNT
ACNT
LCTX
LCTX
Operating Cash FlowLast quarter
$266.0K
$-4.9M
Free Cash FlowOCF − Capex
$-196.0K
$-5.3M
FCF MarginFCF / Revenue
-1.7%
-79.9%
Capex IntensityCapex / Revenue
3.9%
6.0%
Cash ConversionOCF / Net Profit
-5.73×
TTM Free Cash FlowTrailing 4 quarters
$-2.1M
$-19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACNT
ACNT
LCTX
LCTX
Q4 25
$266.0K
$-4.9M
Q3 25
$1.3M
$-3.6M
Q2 25
$-1.4M
$-5.5M
Q1 25
$-700.0K
$-4.9M
Q4 24
$8.8M
$-6.3M
Q3 24
$3.4M
$-5.8M
Q2 24
$2.2M
$-5.2M
Q1 24
$263.0K
$-5.8M
Free Cash Flow
ACNT
ACNT
LCTX
LCTX
Q4 25
$-196.0K
$-5.3M
Q3 25
$695.0K
$-3.6M
Q2 25
$-1.5M
$-5.6M
Q1 25
$-1.0M
$-5.0M
Q4 24
$8.4M
$-6.7M
Q3 24
$3.1M
$-5.9M
Q2 24
$1.9M
$-5.2M
Q1 24
$25.0K
$-5.8M
FCF Margin
ACNT
ACNT
LCTX
LCTX
Q4 25
-1.7%
-79.9%
Q3 25
3.5%
-98.6%
Q2 25
-8.3%
-200.8%
Q1 25
-4.1%
-331.8%
Q4 24
80.6%
-234.0%
Q3 24
15.1%
-156.1%
Q2 24
9.1%
-371.2%
Q1 24
0.1%
-403.1%
Capex Intensity
ACNT
ACNT
LCTX
LCTX
Q4 25
3.9%
6.0%
Q3 25
3.1%
0.3%
Q2 25
0.8%
0.5%
Q1 25
1.3%
6.5%
Q4 24
3.7%
12.7%
Q3 24
1.3%
3.0%
Q2 24
1.0%
3.6%
Q1 24
0.9%
2.6%
Cash Conversion
ACNT
ACNT
LCTX
LCTX
Q4 25
-5.73×
Q3 25
Q2 25
-0.22×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACNT
ACNT

Other$6.1M52%
Transferred At Point In Time$5.7M48%

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

Related Comparisons